Repligen Corp (RGEN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Repligen Corp (RGEN)

RGEN 166.82

+0.2%

Jan 9 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cheryl Galt who wrote (227)	5/22/2000 2:10:00 PM
From: scaram(o)uche	Read Replies (1) of 395

Cheryl: I haven't owned RGEN for ages, and therefore have not followed their SEC disclosures. Thank you, thank you, thank you. Thompson and Bluestone have published together for several years. These guys aren't among the world's dumbies, and I will be paying attention to this new attack. I guess that the next step would be to search the various patent sites for European disclosures from Tolerance Therapeutics, to see if a priority date is to be found. Wouldn't be surprised if Europe rights are gone forever, but that's just a guess. Be careful.... RGEN has failed to mention that Bluestone's manuscript was published back to back in that issue of Science with one from BMY (Linsley et al.), that CTLA-4 was described five years before the Bluestone manuscript, and that the first CTLA-4-related publication (not dealing with in vivo immunosuppression) from the BMY group preceded the Science manuscripts by about a year. Nonetheless..... I'll bet that they have an interesting argument, at least for the U.S. Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next